Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

New weapons in the fight against cancer

01.10.2012
Where are the most promising developments from first-in-human studies?

Several new first-in-man studies for drugs targeted against a range of cancers were released at the ESMO 2012 Congress of the European Society for Medical Oncology in Vienna.

"These studies represent our first glance at some of the drugs that may improve cancer treatment in coming years," said Prof Ahmad Awada, head of the medical oncology clinic at Jules Bordet Institute, Brussels, Belgium, chair of the ESMO 2012 Developmental Therapeutics track. "Today's findings highlight the ways that clinical research is working on cancer therapies that target specific molecular pathways within tumor cells and their microenvironment. At ESMO 2012 this year, interesting early reports will be presented on MEK-, MET- and HSP90 inhibitors as well as studies on drugs targeting EGFR and PI3K and agents active in ALK-positive lung cancer resistant to crizotinib. In addition, new immunotherapeutic strategies and new generations of hormonal agents will be at the menu at this year's ESMO congress."

Key selected studies include:

A proof-of-concept study of ODM-201 in patients with progressive castration-resistant prostate cancer

In a dose-escalation trial, 87% of 15 patients who received a novel androgen receptor agonist called ODM-201 experienced a PSA decrease at 12 weeks. "These early results are very promising, and such are rarely seen in these early trials. ODM-201 might be a new hormonal treatment option, and its efficacy-safety profile seems to be very promising in prostate cancer patients," said study author Dr Christophe Massard from Institute Gustave Roussy. "Unlike other anti-androgens, according to non-clinical data, ODM-201 has minimal or no brain entrance, and thus no testosterone increase in animal models. Therefore ODM-201 could be a promising new drug option for patients with metastatic or non metastatic prostate cancer. The results need to be confirmed in bigger patient population of course."

A dose-escalation study of oral selective c-Met inhibitor EMD 1214063 in patients with advanced solid tumors

The cell surface receptor tyrosine kinase c-Met is an emerging target for cancer treatment. EMD 1214063 is a highly selective, reversible and ATP-competitive c-Met inhibitor that causes growth inhibition and regression of HGF-dependent and HGF-independent tumors in pre-clinical models. This dose-escalation study is ongoing, with some preliminary evidence of clinical response being seen.

Multicenter study of the investigational drug TAK-733, an oral MEK inhibitor

Preliminary data of this trial in patients with advanced solid tumors indicate that TAK-733 is generally well tolerated and pharmacodynamically active with signs of anti-tumor activity in patients with advanced non-hematologic malignancies, say researchers.

Phase II study of HSP90 inhibitor AUY922 in patients with ALK-rearranged or EGFR-mutated advanced lung cancer

Among 121 patients with previously treated non-small cell lung cancer, activity was demonstrated in both ALK+ and EGFR-mutant patients, say investigators. Overall tumor response and progression-free survival rates observed warrant further studies, particularly among EGFR-mutant patients.

Results of a first-in-human study of the ALK inhibitor LDK378 in advanced solid tumors

Investigators report striking activity in ALK+ non-small cell lung cancer patients treated at doses over 400mg who had previously progressed following crizotinib.
Dose-finding study of the ALK/EGFR inhibitor AP26113 in patients with advanced malignancies

AP26113 was well tolerated with preliminary anti-cancer activity in ALK+ patients naive to, or failing, prior crizotinib, researchers say.

ESMO PERSS OFFICE | EurekAlert!
Further information:
http://www.esmo.org

More articles from Health and Medicine:

nachricht Microgel powder fights infection and helps wounds heal
14.11.2018 | Michigan Technological University

nachricht Spread of deadly eye cancer halted in cells and animals
13.11.2018 | Johns Hopkins Medicine

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: A Chip with Blood Vessels

Biochips have been developed at TU Wien (Vienna), on which tissue can be produced and examined. This allows supplying the tissue with different substances in a very controlled way.

Cultivating human cells in the Petri dish is not a big challenge today. Producing artificial tissue, however, permeated by fine blood vessels, is a much more...

Im Focus: A Leap Into Quantum Technology

Faster and secure data communication: This is the goal of a new joint project involving physicists from the University of Würzburg. The German Federal Ministry of Education and Research funds the project with 14.8 million euro.

In our digital world data security and secure communication are becoming more and more important. Quantum communication is a promising approach to achieve...

Im Focus: Research icebreaker Polarstern begins the Antarctic season

What does it look like below the ice shelf of the calved massive iceberg A68?

On Saturday, 10 November 2018, the research icebreaker Polarstern will leave its homeport of Bremerhaven, bound for Cape Town, South Africa.

Im Focus: Penn engineers develop ultrathin, ultralight 'nanocardboard'

When choosing materials to make something, trade-offs need to be made between a host of properties, such as thickness, stiffness and weight. Depending on the application in question, finding just the right balance is the difference between success and failure

Now, a team of Penn Engineers has demonstrated a new material they call "nanocardboard," an ultrathin equivalent of corrugated paper cardboard. A square...

Im Focus: Coping with errors in the quantum age

Physicists at ETH Zurich demonstrate how errors that occur during the manipulation of quantum system can be monitored and corrected on the fly

The field of quantum computation has seen tremendous progress in recent years. Bit by bit, quantum devices start to challenge conventional computers, at least...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

“3rd Conference on Laser Polishing – LaP 2018” Attracts International Experts and Users

09.11.2018 | Event News

On the brain’s ability to find the right direction

06.11.2018 | Event News

European Space Talks: Weltraumschrott – eine Gefahr für die Gesellschaft?

23.10.2018 | Event News

 
Latest News

New findings help to better calculate the oceans’ contribution to climate regulation

15.11.2018 | Life Sciences

Automated adhesive film placement and stringer integration for aircraft manufacture

15.11.2018 | Materials Sciences

Epoxy compound gets a graphene bump

14.11.2018 | Materials Sciences

VideoLinks
Science & Research
Overview of more VideoLinks >>>